Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.P03 in adults with advanced or metastatic CLDN1-positive solid tumors
NL-OMON59135Phase 2Recruiting
- Sponsor
- Alentis Therapeutics
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ALE.P03 in Nonhematologic neoplasms, colorectal cancer (CRC), intrahepatic cholangiocarcinoma (ICC) and 3 more (3 arms), sponsored by Alentis Therapeutics. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and serious adverse events and 4 more. Started Jan 2026; status: recruiting.
02
Drugs
ALE.P03
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)intrahepatic cholangiocarcinoma (ICC)Pulmonary squamous cell carcinomatransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON59135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59135.